Medtronic plc - MDT STOCK NEWS

Medtronic plc (NYSE:MDT) will report its financial results for Q4 and full FY 2022 on May 26, 2022, at 5:45 a.m. CDT. This will include summary financial data for the fiscal year ending on April 29, 2022. A video webcast discussing the results will take place at 7:00 a.m. CDT the same day. Future earnings reports for FY 2023 are scheduled for August 23, November 22, February 21, and May 25, 2023. More details will be provided closer to each earnings date.

Medtronic (NYSE: MDT) announced significant findings from the SPYRAL HTN Global Clinical Program, presented on May 17, 2022, at EuroPCR 2022. The data from the SPYRAL HTN-ON MED and GSR-DEFINE trials demonstrate that the Symplicity Spyral Renal Denervation (RDN) system improves blood pressure control, significantly increasing 'time in target range' (TTR) for patients. The SPYRAL HTN-ON MED trial showed a TTR of 33.7% for RDN patients versus 18.8% for sham, while GSR-DEFINE associated higher TTR with a reduced risk of major cardiovascular events. This highlights RDN as a vital tool in managing hypertension.

Medtronic has received FDA approval for the Onyx Frontier™ drug-eluting stent, an advancement in coronary artery disease treatment. This device enhances deliverability by 16% compared to its predecessor, the Resolute Onyx™ stent, and is designed for complex cases. It features a broad size range, with options for large vessels, and supports patients needing short dual antiplatelet therapy durations. This approval marks a significant milestone in Medtronic's commitment to provide innovative solutions for interventional cardiologists and improve patient outcomes.

Medtronic plc (NYSE: MDT) has successfully completed its acquisition of Intersect ENT, enhancing its ENT portfolio with innovative sinus implants aimed at improving post-operative outcomes and treating nasal polyps. The acquisition, announced on May 13, 2022, includes the PROPEL™ and SINUVA™ product lines, designed to address chronic rhinosinusitis affecting approximately 30 million adults in the U.S. annually. This strategic move is expected to increase Medtronic's market presence and innovation capabilities in the ENT field.

Titan Medical Inc. (Nasdaq: TMDI; TSX: TMD) has received a purchase order worth $2.6 million from Medtronic plc (NYSE: MDT) for surgical instruments and cameras. This order aims to facilitate preclinical activities and assess Titan as a potential manufacturing partner for Medtronic. Interim President and CEO Paul Cataford expressed enthusiasm about this collaboration, noting Titan's expanding manufacturing capabilities in Chapel Hill. Titan is developing the Enos robotic surgical system, focusing on enhancing robotic-assisted surgery.

GE Healthcare and Medtronic have announced a collaboration aimed at enhancing care in Ambulatory Surgery Centers (ASCs) and Office Based Labs (OBLs). This partnership will provide customers with access to a broad range of products, financial solutions, and services. The COVID-19 pandemic has shifted many procedures to outpatient settings, and this trend is expected to grow. The collaboration seeks to address the high costs and complexities associated with expanding ASCs, offering consultative planning and advanced technologies. GE Healthcare's Edison-powered imaging solutions are highlighted as a key offering.

Medtronic and GE Healthcare have announced a collaboration to enhance outpatient care at Ambulatory Surgery Centers (ASCs) and Office Based Labs (OBLs). This partnership aims to address the growing demand for outpatient procedures, fueled by the COVID-19 pandemic and rising disease rates. As CMS approved cardiovascular payments in 2020, the use of fixed c-arm imaging systems has surged in these settings. The collaboration will provide extensive product portfolios, financial solutions, and services to improve workflow and clinical outcomes in outpatient environments.

Medtronic has appointed Dr. Laura Mauri as Chief Scientific, Medical and Regulatory Officer, effective April 25, 2022. This role expands her prior responsibilities and aims to unify the company’s medical and scientific efforts. Dr. Mauri's priorities include enhancing patient safety and engagement, aided by the recent hiring of Dr. Olaf Hedrich as Chief Medical Safety Officer. Joining Medtronic in September 2018, Dr. Mauri has significantly impacted trial design and regulatory advancements. She succeeds Dr. Richard Kuntz, who retires on April 29, 2022.

Medtronic plc (NYSE:MDT) has presented long-term data from the SPYRAL HTN-ON MED trial at the American College of Cardiology's ACC.22 session, demonstrating significant blood pressure reductions achieved through its Symplicity Spyral Renal Denervation (RDN) System. In the first 80 patients, the RDN group showed a reduction of 18.7 mmHg in 24-hour systolic blood pressure after three years compared to 8.6 mmHg in the sham group. Additionally, procedural safety was confirmed with no major adverse events reported. The study aims to support the RDN system's regulatory approval in the U.S.